Publications by authors named "Silu Yang"

Tumor Area Positivity (TAP) score is an emerging score measuring programmed death-ligand 1 (PD-L1) expression in tumors. However, the availability of concordance data between TAP score and other immunohistochemistry scoring methods is limited. We investigated concordance between TAP score and combined positive score (CPS) and the relationship between PD-L1 status and clinical outcomes using gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) and esophageal squamous cell carcinoma (ESCC) samples from patients subsequently treated with tislelizumab.

View Article and Find Full Text PDF

Introduction: Tislelizumab plus investigator-chosen chemotherapy (ICC) demonstrated a statistically significant improvement in overall survival (OS) versus placebo plus ICC in RATIONALE-305 in patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric cancer/gastroesophageal junction cancer (GC/GEJC) in the intent-to-treat population and in patients with programmed death-ligand 1 (PD-L1) Tumor Area Positivity (TAP) score ≥ 5%. The United States Food and Drug Administration Oncologic Drugs Advisory Committee voted (September 2024) against first-line treatment with programmed cell death protein-1 inhibitors in this setting in patients with a PD-L1 combined positive score < 1 or TAP score < 1%, due to an unfavorable benefit-risk profile. Thus, we retrospectively analyzed data from RATIONALE-305 in patients with a PD-L1 TAP score ≥ 1%.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effectiveness and safety of tislelizumab combined with chemotherapy for advanced gastric cancer compared to a placebo with chemotherapy.
  • Conducted from December 2018 to February 2023 across multiple continents, it involved 1,657 adult patients with specific cancer types who had not previously undergone systemic treatment.
  • Results indicated that patients receiving tislelizumab plus chemotherapy experienced significant improvements in overall survival compared to those on placebo and chemotherapy.
View Article and Find Full Text PDF
Article Synopsis
  • Activated immune cells in tumors play a key role in the effectiveness of therapies, and understanding their interactions can enhance the use of immune checkpoint inhibitors like tislelizumab.
  • In studies of cancer patients receiving tislelizumab, higher levels of CD8 T-cells and macrophages were linked to longer survival, particularly when those immune cells were close together in the tumor environment.
  • The results highlight the importance of the collaboration between pro-inflammatory macrophages and cytotoxic T cells in improving treatment outcomes with tislelizumab.
View Article and Find Full Text PDF
Article Synopsis
  • Many patients with advanced solid tumors don't respond well to existing PD-1/PD-L1 treatments, showcasing the need for new inhibitors like BGB-A333.* -
  • This study evaluated BGB-A333's safety and effectiveness both alone and with tislelizumab in patients who progressed after standard therapies, with a focus on determining safe dosage and response rates.* -
  • Results showed a recommended dose of 1350 mg and a 41.7% overall response rate in patients treated with BGB-A333 plus tislelizumab, with some serious side effects noted.*
View Article and Find Full Text PDF

Cancer driven by somatic mutations may express neoantigens that can trigger T-cell immune responses. Since T-cell receptor (TCR) repertoires play critical roles in anti-tumor immune responses for oncology, next-generation sequencing (NGS) was used to profile the hypervariable complementarity-determining region 3 (CDR3) of the TCR-beta chain in peripheral blood samples from 68 gastric cancer patients and 49 healthy controls. We found that most hyper-expanded CDR3 are individual-specific, and the gene usage of TRBV3-1 is more frequent in the tumor group regardless of tumor stage than in the healthy control group.

View Article and Find Full Text PDF
Article Synopsis
  • Tislelizumab, an immunotherapy drug, showed some effectiveness in treating advanced gastroesophageal adenocarcinoma (GEA) in clinical trials, but many patients did not respond, necessitating further investigation into resistance mechanisms and predictive biomarkers.
  • The study analyzed data from 105 GEA patients treated with tislelizumab, focusing on factors like PD-L1 expression, gene signatures, and tumor characteristics to find correlations with treatment success.
  • Results indicated that patients with high PD-L1 expression and low hyperamplification had better outcomes, with improved immune responses and longer survival rates, suggesting that these combined biomarkers could help identify suitable candidates for tislelizumab therapy.
View Article and Find Full Text PDF
Article Synopsis
  • - Tislelizumab is a new monoclonal antibody designed to inhibit PD-1, aimed at enhancing anti-tumor activity by reducing T-cell clearance that can lead to resistance against similar treatments.
  • - A phase 1/2 study assessed its safety and effectiveness in treating advanced solid tumors in adult Chinese patients, confirming a recommended dosing of 200 mg every three weeks and monitoring for adverse effects.
  • - Out of 300 treated patients, 18% demonstrated a confirmed clinical response, with mild side effects predominantly reported, such as anemia and increased liver enzymes.
View Article and Find Full Text PDF
Article Synopsis
  • Primary microcephaly is linked to mutations in genes like WDR62 and KIF2A, but understanding its mechanisms is still challenging.
  • Research using mutant mice and human brain organoids showed that deleting WDR62 reduces brain and organoid size by affecting neural progenitor cells (NPCs), particularly outer radial glia (oRG).
  • The study uncovered that WDR62 works with CEP170 to affect cilium disassembly and NPC proliferation, suggesting that the disruption of this function contributes to microcephaly.
View Article and Find Full Text PDF

Zika virus (ZIKV) infection of pregnant women can result in fetal brain abnormalities. It has been established that ZIKV disrupts neural progenitor cells (NPCs) and leads to embryonic microcephaly. However, the fate of other cell types in the developing brain and their contributions to ZIKV-associated brain abnormalities remain largely unknown.

View Article and Find Full Text PDF

How neural progenitor cell (NPC) behaviors are temporally controlled in early developing embryos remains undefined. The in vivo functions of microRNAs (miRNAs) in early mammalian development remain largely unknown. Mir-302/367 is a miRNA cluster that encodes miR-367 and four miR-302 members (miR302a-d).

View Article and Find Full Text PDF

Neural progenitor cells (NPCs) have distinct proliferation capacities at different stages of brain development. Lin28 is an RNA-binding protein with two homologs in mice: Lin28a and Lin28b. Here we show that Lin28a/b are enriched in early NPCs and their expression declines during neural differentiation.

View Article and Find Full Text PDF

Detecting associations between human genetic variants and their phenotypic effects is a significant problem in understanding genetic bases of human-inherited diseases. The focus is on a typical type of genetic variants called non-synonymous single nucleotide polymorphisms (nsSNPs), whose occurrence may potentially alter the structures of proteins, affecting functions of proteins, and thereby causing diseases. Most of the existing methods predict associations between nsSNPs and diseases based on features derived from only protein sequence and/or structure information, and give no information about which specific disease an nsSNP is associated with.

View Article and Find Full Text PDF

In Neurospora crassa, the methionine synthase gene met-8 plays a key role in methionine synthesis. In this study, we found that MET-8 protein levels were compromised in several mutants defective in proper heterochromatin formation. Bioinformatics analysis revealed a 50-kb AT-rich region adjacent to the met-8 promoter.

View Article and Find Full Text PDF

DNA methylation and H3K9 trimethylation are involved in gene silencing and heterochromatin assembly in mammals and fungi. In the filamentous fungus Neurospora crassa, it has been demonstrated that H3K9 trimethylation catalyzed by histone methyltransferase DIM-5 is essential for DNA methylation. Trimethylated H3K9 is recognized by HP1, which then recruits the DNA methyltransferase DIM-2 to methylate the DNA.

View Article and Find Full Text PDF

To evaluate the treatment capability of subsurface flow constructed wetland (SFCW) and the effect of salinity on the degradation of atrazine, the degradation of atrazine in SFCW was studied. Under the static condition, the degradation of atrazine in SFCW followed first-order kinetics: c=0.09679 exp(-0.

View Article and Find Full Text PDF

The fate of dissolved organic matter (DOM) during horizontal subsurface-flow constructed wetlands (HSSF CWs) was examined. In several studies it had been demonstrated that factors such as vegetation and substrates type affected the treatment efficiency of DOM, while very few studies discerned their influence on the transformations of DOM. Thus three pilot-scale HSSF CWs, i.

View Article and Find Full Text PDF